Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1537-1546

  Bagley, Rebecca G ^a   Kurtzberg, Leslie ^a   Rouleau, Cecile ^a   Yao, Min ^a   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Alkylphosphocholine; Bone marrow; Cancer; Erufosine; Lipid; Toxicity

Indexed keywords

EDELFOSINE; ERUFOSINE; MILTEFOSINE; PERIFOSINE; PHOSPHORYLCHOLINE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; GLIOBLASTOMA; GRANULOCYTE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; PHOSPHORIC ACID ESTERS; PROTO-ONCOGENE PROTEINS C-AKT; QUATERNARY AMMONIUM COMPOUNDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82455175173     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1658-0     Document Type: Article

References (49)

1. C Gajate F Mollinedo 2000 Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood 109 719 771
2. F Mollinedo JL Fernandez-Luna C Gajate B Martin-Martin A Benito R Martinez-Dalmau M Modolell 1997 Selective induction of apoptosis in cancer cells by either lipid ET-18-OCH3 (edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L) Cancer Res 57 1320 1328 9102220 1:CAS:528:DyaK2sXit1Ogsbo%3D (Pubitemid 27152558)
3. WE Berdel U Fink J Rastetter 1987 Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3 Lipids 22 967 969 3328029 10.1007/BF02535566 1:STN:280:DyaL1c7nsVajug%3D%3D (Pubitemid 18001407)
4. B Khanavkar F Ulbrich U Gatzemeier E Meyer-Schwickerath J Lorenz W Schreml R Brugger HD Schick JV Pawel R Nordstrom P Drings 1989 Treatment of non-small cell lung cancer with the alkyl lysophospholipid edelfosine Contrib Oncol 37 224 235
5. AH van der Luit SR Vink JB Klarenbeek D Perrissoud E Solary M Verheij WJ van Blitterswijk 2007 A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells Mol Cancer Ther 6 2337 2345 17699729 10.1158/1535-7163.MCT-07-0202 (Pubitemid 47294762)
6. GA Ruiter SF Zerp H Bartelink WJ van Blitterswijk M Verheij 1999 Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis Cancer Res 59 2457 2463 10344758 1:CAS:528:DyaK1MXjsVygurw%3D (Pubitemid 29242297)
7. WJ van Blitterswijk M Verheij 2008 Anticancer alkylphopholipids: mechanism of action, cellular sensitivity and resistance, and clinical prospects Curr Pharma Design 14 2061 2074 10.2174/138161208785294636
8. P Hilgard T Klenner J Stekar C Unger 1993 Alkylphosphocholines: a new class of membrane-active anticancer agents Cancer Chemother Pharmacol 32 90 95 8485813 10.1007/BF00685608 1:CAS:528:DyaK3sXlvFCru7g%3D (Pubitemid 23131925)
9. S Sundar TK Jha CP Thakur J Engel H Sindermann C Fischer K Junge A Bryceson J Berman 2002 Oral miltefosine for Indian visceral leishmaniasis NEJM 347 1739 1746 12456849 10.1056/NEJMoa021556 1:CAS:528:DC%2BD38XpsV2js7c%3D (Pubitemid 35375612)
10. F Widmer LC Wright D Obando R Handke R Ganendren DH Ellis TC Sorrell 2006 Hexadecylphosphocholine (Miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis Antimicrobial Agents Chemother 50 414 421 10.1128/AAC.50.2.414-421.2006 1:CAS:528: DC%2BD28XhsFegtro%3D (Pubitemid 43190947)
11. R Leonard J Hardy G van Tienhoven S Houston P Simmonds M David J Mansi 2001 Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer J Clin Oncol 19 4150 4159 11689583 1:CAS:528:DC%2BD3MXosFSmtb0%3D (Pubitemid 33049533)
12. R Dummer J Roger T Vogt J Becker H Hefner H Sindermann G Burg 1992 Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas Prog Exp Tumor Res 34 160 169 1438799 1:STN:280:DyaK3s%2FmslShsw%3D%3D
13. J Kotting NW Marschner W Neumuller C Unger H Eibl 1992 Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution Prog Exp Tumor Res 34 131 142 1438796 1:STN:280:DyaK3s%2FmslSiug%3D%3D
14. J Verweij K Krzemieniecki T Kok A Poveda C Van Pottelsberghe M Can Glabbeke H Mourisden 1993 Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult-an EORTC Soft Tissue and Bone Sarcoma Group study Eur J Cancer 29A 208 209 8422284 10.1016/0959-8049(93)90177-H 1:STN:280:DyaK3s7jsF2hsQ%3D%3D
15. AS Planting G Stoter J Verweij 1993 Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer Eur J Cancer 29A 208 209
16. J Verweij D Gandia AS Planting G Stoter JP Armand 1993 Phase II study of oral miltefosine in patients with squamous cell head and neck cancer Eur J Cancer 29A 778 779 8471342 10.1016/S0959-8049(05)80369-7 1:STN:280: DyaK3s3ivFWntQ%3D%3D (Pubitemid 23077068)
17. T Hideshima L Catley H Yasui K Ishitsuka N Raje C Mitsiades K Podar NC Munshi D Chauhan PG Richardson KC Anderson 2006 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood 107 4053 4062 16418332 10.1182/blood-2005-08-3434 1:CAS:528:DC%2BD28XkvFWgsrs%3D (Pubitemid 43726814)
18. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E. (2006) A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 5:766-770 (Pubitemid 44775131)
19. M Crul H Rosing GJ de Klerk R Dubbelman M Traiser S Reichert NG Knebel JH Schellens JH Beijnen WW ten Bokkel Huinink 2002 Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumors Eur J Cancer 33 442 446
20. DS Ernst E Eisenhauer N Wainman M Davis R Lohmann T Baetz K Belanger M Smylie 2005 Phase II study of perifosine in previously untreated patients with metastatic melanoma Invest New Drugs 205 23 1 7
21. M Knowling M Blackstein R Tozer V Bramwell J Dancey N Dore S Matthews E Eisenhauer 2006 A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial Invest New Drugs 24 435 439 16528479 10.1007/s10637-006-6406-7 1:CAS:528:DC%2BD28XlsVCisbg%3D (Pubitemid 43876080)
22. NB Leighl S Dent M Clemons TA Vandenberg R Tozer DC Warr RM Crump D Hedley, et al. 2008 A phase 2 study of perifosine in advanced or metastatic breast cancer Breast Cancer Res Treat 108 87 92 17458693 10.1007/s10549-007- 9584-x 1:CAS:528:DC%2BD1cXitVKmt7s%3D (Pubitemid 351623244)
23. EM Posadas J Gulley PM Alren A Trout HL Parnes J Wright MJ Lee EJ Chung JB Trepel A Sparreboom C Chen E Jones SM Steinberg A Daniels WD Giff WL Dahut 2005 A phase II study of perifosine in androgen independent prostate cancer Cancer Biol Ther 4 1133 1137 16138006 10.4161/cbt.4.10.2064 1:CAS:528: DC%2BD28XkvFGhu78%3D (Pubitemid 41598570)
24. Bendell JC, Richards DA, Vukelia SJ, Campos LT, Hagenstad CT, Letzer JP, Neumunaitis JJ (2010) Randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC). ASCO Gastroint Cancer Sym: Abstr#447
25. Richard DA, Neumunaitis JJ, Vukelja SJ, Hagenstad CT, Campos LT, Letzer JP, Hermann RC, Sportelli P, Gardner LR, Bendell JC (2010) Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC). J Clin Oncol 28(suppl):Abstr#3531
26. Greco FA, Infante JR, Burris HA, Jones SF, Kolesar J, Gardner LR, Sportelli P, Bendell JC (2010) Safety and pharmacokinetics (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 28(suppl):Abstr#e14086
27. MR Berger S Sobottka SM Konstantinov H Eibl 1998 Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines Drugs Today 34 73 81 1:CAS:528:DyaK1MXhtVyrt7k%3D (Pubitemid 29046798)
28. P Kaufmann-Kolle MR Berger C Unger Systemic administration of alkylphosphocholines, et al. 1996 Erucylphosphocholine and liposomal hexadecylphosphocholine Adv Exp Med Biol 416 165 168 9131143 1:CAS:528:DyaK2sXkslCksrw%3D
29. B Erdlenbruch V Jendrossek M Marx A Hunold H Eibl M Lakomek 1998 Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo Anticancer Res 18 2551 2558 9703909 1:CAS:528:DyaK1cXlsF2hsrY%3D
30. V Jendrossek B Erdlenbruch A Hunold W Kugler H Eibl M Lakomek 1999 Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro Int J Onc 14 15 22 1:CAS:528:DyaK1MXktlKhuw%3D%3D
31. V Jendrossek K Hammersen B Erdlenbruch W Kugler R Krugener H Eibl M Lakomek 2002 Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro Cancer Chemother Pharmacol 50 71 79 12111115 10.1007/s00280-002-0440-8 1:CAS:528:DC%2BD38XkvVansr4%3D (Pubitemid 34743999)
32. MC Georgieva SM Konstantinov M Topashka-Ancheva MR Berger 2002 Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells Cancer Lett 182 163 174 12048162 10.1016/S0304- 3835(02)00088-5 1:CAS:528:DC%2BD38XktFKgsro%3D (Pubitemid 34621180)
33. AM Martelli V Papa PL Tazzari F Ricci C Evangelisti F Chiarini, et al. 2010 Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms Leukemia 24 687 698 20200557 10.1038/leu.2010.32 1:CAS:528:DC%2BC3cXks1Kmu7o%3D
34. M Fiegl LH Lindner M Jergens H Eibl W Hiddemann J Braess 2008 Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs Cancer Chemother Pharmacol 62 321 329 17922125 10.1007/s00280-007-0612-7 1:CAS:528:DC%2BD1cXlvVWitLY%3D (Pubitemid 351692092)
35. SK Konigs CP Pallasch LH Lindner J Schwamb A Schulz R Brinker, et al. 2010 Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway Leuk Res 34 1064 1069 20092894 10.1016/j.leukres.2009. 12.003
36. SM Konstantinov MR Berger 1999 Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines Cancer Lett 144 153 160 10529015 10.1016/S0304-3835(99)00219-0 1:CAS:528:DyaK1MXlvVWltLY%3D (Pubitemid 29457657)
37. Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SP, Berger MR (2010) Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol 67:13-25
38. LH Lindner H Eibl M Hossann M Vogeser 2008 Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard J Chromat 869 16 19 10.1016/j.jchromb.2008.05.007 1:CAS:528:DC%2BD1cXnt1altLk%3D
39. A Rubel R Handrick LH Lindner M Steiger H Eibl W Budach C Belka V Jendrossek 2006 The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro Radiation Oncol 1 6 23 10.1186/1748-717X-1-6
40. JJ Gillis PA Dennis 2009 Perifosine: update on a novel Akt inhibitor Curr Oncol Reports 11 102 110 10.1007/s11912-009-0016-4
41. R Handrick A Rubel H Faltin H Eibl C Belka V Jendrossek 2006 Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling Radiother Oncol 80 199 206 16916558 10.1016/j.radonc.2006.07. 021 1:CAS:528:DC%2BD28Xptlyks78%3D (Pubitemid 44301537)
42. MM Zaharieva SM Konstantinov B Pilicheva M Karaivanova MR Berger 2007 Erufosine, a membrane targeting antineoplastic agent with signal transduction modulating effects Ann NY Acad Sci 1095 182 192 17404031 10.1196/annals.1397.022 1:CAS:528:DC%2BD2sXks1GktLk%3D (Pubitemid 47092450)
43. Yosifov DY, Dineva IK Zaharieva MM, Konstantinov SP, Berger MR (2007) The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3). Cancer Biol Ther 930-935 (Pubitemid 351574984)
44. 1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines Apoptosis 15 753 768 20107899 10.1007/s10495-010-0460-5 1:CAS:528:DC%2BC3cXotVOltb0%3D
45. VV Lemeshko W Kugler 2007 Synergistic inhibition of mitochondrial respiration by anticancer agent erucylphosphohomocholine and cyclosporine A J Biol Chem 282 37303 37307 17993460 10.1074/jbc.C700134200 1:CAS:528: DC%2BD2sXhsVGjtr%2FN
46. B Erdlenbruch V Jendrossek A Gerriets F Vetterlein H Eibl M Lakomek 1999 Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration Cancer Chemother Pharmacol 44 484 490 10550569 10.1007/s002800051122 1:CAS:528:DyaK1MXntVamt74%3D (Pubitemid 29501018)
47. IM Ghobrial A Roccaro F Hong E Weller N Rubin R Leduc M Rourke S Chuma, et al. 2010 Clinical and translation studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's Macroglobulinemia Clin Cancer Res 16 1033 1041 20103671 10.1158/1078-0432.CCR- 09-1837 1:CAS:528:DC%2BC3cXhs1aru7w%3D
48. Z Li F Tan DJ Liewehr SM Seinberg CJ Thiele 2010 In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine JNCI 102 758 770 20463309 1:CAS:528:DC%2BC3cXntVGhsr0%3D
49. SR Vink W van Blitterswijk JHM Schellens M Verheij 2007 Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy Cancer Treatment Rev 33 191 202 10.1016/j.ctrv.2006.12.001 1:CAS:528:DC%2BD2sXitl2jtLg%3D (Pubitemid 46323398)